• español
    • English
  • Login
  • español 
    • español
    • English

UniversidaddeCádiz

Área de Biblioteca, Archivo y Publicaciones
Comunidades y colecciones
Ver ítem 
  •   RODIN Principal
  • Producción Científica
  • Artículos Científicos
  • Ver ítem
  •   RODIN Principal
  • Producción Científica
  • Artículos Científicos
  • Ver ítem
JavaScript is disabled for your browser. Some features of this site may not work without it.

Safety and efficacy of convalescent plasma for COVID-19 in the pre-vaccine era, and implementation in a large healthcare system: A phase I/II randomized, multicentre clinical trial (PC-COVID)

Thumbnail
Identificadores

URI: http://hdl.handle.net/10498/40626

DOI: 10.1016/J.EIMC.2026.503166

ISSN: 1578-1852

ISSN: 0213-005X

Ficheros
OA_2026_0606.pdf (1.065Mb)
Estadísticas
Ver estadísticas
Métricas y Citas
 
Compartir
Exportar a
Exportar a MendeleyRefworksEndNoteBibTexRIS
Metadatos
Mostrar el registro completo del ítem
Autor/es
Caponcello, Maria Giulia; Macías Sánchez, Maria del Mar; Macías, Juan; Aguilar Guisado, Manuela; Romero Palacios, AlbertoAutoridad UCA; Retamar Gentil, Pilar; Márquez-Gómez, Ignacio; Martínez-Marcos, Francisco Javier; López Cardenas, SalvadorAutoridad UCA; Marrugal Lorenzo, Jose Antonio; Quijano Ruiz, Blanca; Mata, Rosario; Carmona Sánchez, Gloria; Oyonarte, Salvador; Rodríguez Baño, Jesús
Fecha
2026-03-31
Departamento/s
Cirugía; Medicina
Fuente
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 44, Núm. 6, 2026
Resumen
Introduction: A phase 2 trial was conducted to evaluate the safety and efficacy of convalescent plasma (CP) for patients admitted with COVID-19 in the pre-vaccine era. Methods: CP was compared to standard of care (SoC) in a randomized clinical trial in patients admitted with COVID-19 pneumonia and with either hypoxia and/or some underlying condition from April to December 2020 in 15 hospitals in Andalusia, Spain. The primary endpoints were adverse events and failure (all-cause death and need for mechanical ventilation during the first 21 days). Result: The procedure for CP was developed and worked properly. Overall, 72 patients of 88 evaluated were recruited (37 and 35) assigned to CP and SoC. Median duration of COVID-19 related symptoms was 7 and 6 days, and median oxygen saturation at randomization was 93% and 92.5% in experimental and control arms, respectively. Overall, 8 (21.6%) patients in the experimental CP group (non related to CP) and 8 (22.9%) in the control group developed grade 3 adverse events (relative risk [RR] 0.94; 95% CI: 0.39–2.24); failure occurred in 3 (8.1%) and 4 (11.4%) patients, respectively ([RR] 0.94, CI: 0.14–6.35 for both events). No differences in secondary endpoints (change in inflammatory parameters, negativization of SARS-CoV-2 PCR or duration of hospital stay) were found. Conclusions: The results suggested that CP is safe for use in COVID-19 patients, although no significant efficacy signal could be observed. A successful regional system for CP administration was developed.
Materias
COVID-19; Convalescent plasma; Clinical trial
Colecciones
  • Artículos Científicos [12034]
Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Esta obra está bajo una Licencia Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 Internacional

Listar

Todo RODINComunidades y ColeccionesPor fecha de publicaciónAutoresTítulosMateriasEsta colecciónPor fecha de publicaciónAutoresTítulosMaterias

Mi cuenta

AccederRegistro

Estadísticas

Ver Estadísticas de uso

Información adicional

Acerca de...Deposita en RODINPolíticasNormativasDerechos de autorEnlaces de interésEstadísticasNovedadesPreguntas frecuentes

RODIN está accesible a través de

OpenAIREOAIsterRecolectaHispanaEuropeanaBaseDARTOATDGoogle Académico

Enlaces de interés

Sherpa/RomeoDulcineaROAROpenDOARCreative CommonsORCID

RODIN está gestionado por el Área de Biblioteca, Archivo y Publicaciones de la Universidad de Cádiz

ContactoSugerenciasAtención al Usuario